[
    [
        {
            "time": "",
            "original_text": "康泰生物：公司药品生产许可证变更，具备生产新型冠状病毒灭活疫苗(Vero细胞)的基础条件",
            "features": {
                "keywords": [
                    "康泰生物",
                    "药品生产许可证",
                    "新冠疫苗",
                    "Vero细胞"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物：公司药品生产许可证变更，具备生产新型冠状病毒灭活疫苗(Vero细胞)的基础条件",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "康泰生物(300601.SZ)：公司药品生产许可证变更具备生产新型冠状病毒灭活疫苗(Vero细胞)的基础条件",
            "features": {
                "keywords": [
                    "康泰生物",
                    "300601.SZ",
                    "药品生产许可证",
                    "新冠疫苗",
                    "Vero细胞"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "康泰生物(300601.SZ)：公司药品生产许可证变更具备生产新型冠状病毒灭活疫苗(Vero细胞)的基础条件",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报：从历史复盘看“高景气度龙头”抱团趋势",
            "features": {
                "keywords": [
                    "医药行业",
                    "周报",
                    "高景气度",
                    "龙头",
                    "抱团趋势"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：从历史复盘看“高景气度龙头”抱团趋势",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报：维持行业长期看好观点 持续关注创新与高景气细分领域",
            "features": {
                "keywords": [
                    "医药行业",
                    "周报",
                    "长期看好",
                    "创新",
                    "高景气细分领域"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：维持行业长期看好观点 持续关注创新与高景气细分领域",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物/行业周报：关注业绩超预期的机会",
            "features": {
                "keywords": [
                    "医药生物",
                    "周报",
                    "业绩超预期",
                    "机会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物/行业周报：关注业绩超预期的机会",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]